pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,334 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1024Endpoints775BioPharma Dive297BioSpace214Fierce Biotech203onclive165raps74globenewswire health
therapy area
allOncology6025Rare Disease1434Cardiology1089Hematology1024Immunology998Vaccines901Pulmonology
  • Capricor sues Nippon Shinyaku over Duchenne drug 'pricing flaw' and launch prep
    Capricor Therapeutics said Thursday it has filed a lawsuit against Nippon Shinyaku over a distribution and commercialization agreement for deramiocel, a cell therapy candidate for Duchenne muscular…
    Endpoints · 3mo ago↗ source
  • Opinion: We need more men in nursing
    Men make up just 12% of nurses nationally. That needs to change.
    STAT · 3mo ago↗ source
  • Opinion: STAT+: Medicare’s new RAPID pathway is a breakthrough for adults. Children are still waiting
    “The pediatric and orphan pipeline is already the smallest, slowest, and least capitalized segment of the device industry,” writes Kolaleh Eskandanian.
    STAT · 3mo ago↗ source
← prev
page 79 of 94
next →
73
fda recalls47
fda medwatch37
fda press28
899
Psychiatry & CNS712
Ophthalmology421
Endocrinology & Metabolism380
Pain373
Infectious Disease353
  • Why we left the FDA: Six former officials share their stories
    In this week's STATus Report, hear from six former FDA officials on why they left the agency.
    STAT · 3mo ago↗ source
  • Odyssey raises more than $300M as biotech goes public
    Odyssey Therapeutics pulled together $279 million from its initial public offering, the autoimmune disease drug developer said Thursday night. Odyssey began trading on the Nasdaq on Friday. The bio…
    Endpoints · 3mo ago↗ source
  • Odyssey, on second try, snags $279M in an IPO
    After withdrawing its initial filing last year, the immune drugmaker rebounded and added to a recent run of sizable new biotech stock offerings — while boosting its haul even higher through a concu…
    BioPharma Dive · 3mo ago↗ source
  • Dr Sznol on Optimal Treatment Sequencing in Melanoma
    Mario Sznol, MD, discusses the challenges of determining whether to recommend adjuvant therapy for patients with melanoma based on current data.
    onclive · 3mo ago↗ source
  • Fraudulent citations, blamed on AI hallucinations, are becoming more common in research papers
    “Fabricated” citations that do not reference real academic papers are spreading in the literature, polluting the public record of science, a new study found
    STAT · 3mo ago↗ source
  • Astellas touts data from early test of stem cell-derived eye therapy
    Astellas reported promising results with its stem cell-derived therapy in an age-related eye disease, though data in a handful of high-dose patients in the early-stage study raised questions. The e…
    Endpoints · 3mo ago↗ source
  • Mentorship Is Key to Advance the Next Generation of Oncology Researchers
    Theresa A. Guise, MD, FASBMR, and Stephanie S. Watowich, PhD, discuss their elections as AAAS fellows and offer guidance for early-career investigators.
    onclive · 3mo ago↗ source
  • Dr Mauro on the Significance of Alternative TKI Formulations in CML
    Michael Mauro, MD, details the FDA approval of the small-molecule formulation of dasatinib and other alternate TKI formulations in chronic myeloid leukemia.
    onclive · 3mo ago↗ source
  • Sarepta tumbles as its gene therapy sales decline further
    Even though Elevidys beat Wall Street expectations, analysts expect investor focus to shift toward Sarepta's early-stage RNA drugs.
    BioPharma Dive · 3mo ago↗ source
  • Key takeaways from WHO briefing on hantavirus cruise ship outbreak
    Here are key takeaways from a WHO briefing on the hantavirus outbreak aboard a cruise ship.
    STAT · 3mo ago↗ source
  • Women With Bladder Cancer Face Diagnostic Delays as Symptoms Mimic UTIs, Experts Warn
    Timothy N. Clinton, MD, and Stephanie A. Berg, DO, discuss gender differences in bladder cancer during Bladder Cancer Awareness Month.
    onclive · 3mo ago↗ source
  • Seaport’s IPO adventure, obesity pill battles, and Makary’s troubles
    This week on "The Readout LOUD" podcast: Seaport Therapeutics’ successful IPO, obesity pill battles, and the FDA commissioner's White House troubles.
    STAT · 3mo ago↗ source
  • Science is becoming less disruptive. Is an aging workforce to blame?
    Most researchers conduct their more disruptive work early in their careers, but as they age, they tend to abandon that groundbreaking energy
    STAT · 3mo ago↗ source
  • Amazon adds Ozempic pill to same-day prescription drug kiosks
    The Ozempic pill is coming to Amazon Pharmacy’s prescription drug kiosks. It’s an expansion for the kiosks, which operate like vending machines and have been stocking oral Wegovy since February. Am…
    Endpoints · 3mo ago↗ source
  • Dr Olawaiye on the FDA Approval of Relacorilant Plus Nab-Paclitaxel in PROC
    Alexander B. Olawaiye, MD, discusses the clinical significance of the FDA approval of relacorilant plus nab-paclitaxel in PROC.
    onclive · 3mo ago↗ source
  • Official leading CDC’s cruise ship program retires
    The hantavirus outbreak on the MV Hondius has focused the public's attention on cruise ship safety.
    STAT · 3mo ago↗ source
  • Daraxonrasib Monotherapy Elicits Meaningful Responses in Previously Treated, RAS-Mutated Pancreatic Cancer
    Phase 1/2 data showed an ORR of 35% with daraxonrasib in second-line RAS G12-mutated pancreatic ductal adenocarcinoma.
    onclive · 3mo ago↗ source
  • Sylvester Comprehensive Cancer Center Identifies a Screening Gap to Prevent a Type of Leukemia in the U.S.
    Researchers at Sylvester identified populations in the US where this cancer may be largely preventable by addressing mother‑to‑child transmission of the virus.
    onclive · 3mo ago↗ source
  • EnGene's shares crash on updated pivotal bladder cancer data
    EnGene’s latest Phase 2 results on an experimental treatment for certain bladder cancer patients alarmed investors and raised concerns around the therapy’s future prospects. The Canadian biotech's…
    Endpoints · 3mo ago↗ source
  • Are health insurers out of the woods after a tough 2025?
    Last year, health insurer after health insurer slashed or withdrew their profit outlooks after being sucker-punched by high medical costs. This year is shaping up ...
    Endpoints · 3mo ago↗ source
  • Blackstone puts $250M into Anagram to tackle cystic fibrosis complication
    Blackstone Life Sciences, fresh off one of the largest private investment funds in industry history, is putting $250 million to work on a little-known biotech seeking to drastically reduce the numb…
    Endpoints · 3mo ago↗ source
  • FDA Completes Type A Meeting Following CRL for Tabelecleucel in EBV+ R/R Post-Transplant Lymphoproliferative Disease
    The FDA and Atara Biotherapeutics completed a Type A meeting to discuss the CRL for tabelecleucel in post-transplant lymphoproliferative disease.
    onclive · 3mo ago↗ source